
'Hallway of sadness' transformed by patients' art at Ottawa hospital
Tucked between patient rooms on the 5 North unit at Ottawa's Bruyère Health Saint-Vincent Hospital, a quiet hallway serves as a daily passage for staff and visitors alike.
But the corridor once referred to as "the hallway of sadness" is about to take on a new identity.
With Hallways of Hope, a new initiative led by Bruyère chaplain Roshene Lawson, residents of the long-term care unit have been invited to turn the once "gloomy" corridor into a vibrant gallery of their own making.
After several months of work, a temporary exhibit held at the hospital last week offered a preview.
Each piece is different, shaped by its own inspiration and technique. Some are deeply personal: a dog named Casey, a memory of Spain and even a forest rendered in thumbprints and coffee grounds.
Created with the help of Ottawa artist Christopher Griffin, the works reflect each patient's ability — and willingness — to try. Some held pencils in their mouths. Others used their hands. Most had never painted before.
A comment that sparked a movement
The idea began with a moment of honesty.
"Back in November, we were dealing with a realization of how dark things can be on our unit," said Dr. Chris Kirby, a physician on 5 North. "The burden of illness that our patients were shouldering … affects everybody — them, but also their caregivers."
During rounds, Kirby made a passing remark about the atmosphere on the unit. "I kind of made this backhanded comment about how it was the hallway of sadness," he recalled.
Lawson, the chaplain, heard the comment and invited Kirby to discuss it. "I was kind of like a teacher after class saying, 'You need to stay after and talk to me,'" she recalled. "I could tell he was struggling with the burden of what his patients were carrying."
Many patients on the unit live with ALS, also known as Lou Gehrig's disease, or other degenerative neuromuscular conditions. Some have lost speech, others mobility. Most face slow, progressive decline — and a hospital setting that can feel "very grey," as Kirby put it.
"You're here for a long time. These are days that blend into each other," he said.
For Lawson, the unit's role isn't just clinical — it's about human relationships.
"Five North is not necessarily about a cure," she said. "It's about accompaniment — how we accompany our patients and families and each other on this unit. The journeys can be dark and a burden, but there can also be joy in darkness."
Inspired, Kirby reframed his thoughts of the corridor. "You can't be focused on the negative," he said. "So I spun it and said, 'OK — hallway of hope.'"
Lawson picked up the phone and called local muralist Griffin with a pitch: "There's no money in it," she warned him. "But there's great joy and purpose in it — and great meaning."
Griffin immediately said yes.
Where memories meet the canvas
Each painting on display in the 5 North exhibit carries more than colour and texture — it carries a story.
For Badrudduza Kazi, whose ALS has left him unable to hold a brush, the medium became as important as the message. Using coffee grounds and his thumb, he created Golden Quiet, a warm, pastoral landscape dotted with trees and sunlight.
"It's a hope of life," he said softly, looking over the canvas. Kazi, who's unable to move his hands or fingers, credits Griffin with helping him believe he could still create. And he did.
Griffin helped adapt each technique to the abilities of each patient.
"I would dip their fingers into coffee grounds, and we'd basically finger paint," he said. "We had to rotate the canvas as we worked, because of their mobility — they could only reach so far. So we ended up painting landscapes sideways and even upside down."
Kim Otte, another patient and contributor, was inspired by the memory of southern Spain. His painting, Malaga Sun, channels the warmth and calm he remembers from his time living in Europe.
"I was asked to pick a place that was perhaps the most positive experience," he said. "This is the part of Malaga in southern Spain … it's a very serene place, beautiful climate. I have many, many happy memories from that place."
Otte also appreciated the fact that the paintings will be on permanent display. "Because obviously at some point I'm not going to be here … you put a little fingerprint on the place," he said.
Another participant, Martin Meech, painted a scene based on his childhood memories at a lake near Lac Long in Quebec. His work, Where the Trees Remember, is rich with coffee-textured trees and orange foliage.
"At the end, I couldn't believe it," Meech said. "It was just wonderful."
The painting helps him return to a time he still holds dear. "It reminds me of everything — especially our cottage," he said. "The trails, the nature — everything."
Meech said he hopes others take away the same sense of optimism that the project brought him.
"If people stay positive, they do a lot better," he said. "And hope brings them positivity."
The exhibit has drawn praise from families, staff and even patients who once said they'd never hold a brush. But for those involved, the real transformation happened well before the first canvas was hung — in the quiet moments of creation, conversation and care.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
19 minutes ago
- CTV News
York police charge doctor with two counts of sexual assault
Police in York Region have arrested a doctor on sexual assault charges. York's Criminal Investigations Bureau have charged a doctor with sexual assault after a victim reported two incidences. Police say the person attended a medical clinic on Markham Road. During the visit, the person said the doctor touched them in a sexual manner. The victim left immediately and reported the incident to the police. While telling police of the experience, the person also recalled a previous appointment at the same clinic in November 2023, when the doctor's actions were also inappropriate. At that time, the person didn't report the event because they believed the conduct might have been part of a legitimate medical procedure. Police are asking the public to review the photo of Dr. Saber Abdel Malouka Abdel Malak, 62, of Whitchurch-Stouffville who has been a physician for more than 30 years. Police say a sexual assault includes any non-consensual contact of a sexual nature. They encourage anyone who feels they may have been a victim to report the incident to the police. To make an online report click here. Anyone with information is asked to call the York Regional Police Special Victims Unit at 1-866-876-5423, ext. 7071. Anonymous tips can be made by calling Crime Stoppers at 1-800-222-TIPS.

National Post
19 minutes ago
- National Post
Pluristyx Completes Investment Round to Expand Product Portfolio and Commercial Operations
Article content SEATTLE — Pluristyx, a leading provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, today announced the successful close of its most recent round of funding led by BioLife Solutions, the global leader in cryopreservation technologies and systems that support cell and gene therapy (CGT) manufacturing, and BroadOak Capital Partners, a specialist investor in the life science tools and services industry. Article content The newly raised capital will enable Pluristyx to expand inventory with new clinical grade cell lines incorporating Pluristyx's proprietary FailSafe® and iACT™ engineering and hypoimmune genetic edits in its best-in-class, polyclonal, synthetic RNA reprogramed iPSCs. These proprietary cells are specifically designed to support making next-generation genetically engineered, stem cell-derived therapies and support uniquely safe, effective, and scalable living medicines. The funding will also support Pluristyx's recently launched PluriForm ™ kit, which provides researchers with streamlined tools for generating organoids and other complex test systems. Article content 'We are incredibly excited for the successful close of this round and gratified to have industry leaders and peers validate our vision with their investment,' said Benjamin Fryer, PhD, CEO of Pluristyx. 'The support from our Seattle area neighbor, BioLife Solutions, and continued support from our colleagues at BroadOak Partners will allow us to manufacture, commercialize, and distribute our innovative solutions and help our customers solve critical industry challenges.' Article content Roderick de Greef, BioLife's Chairman and CEO, remarked, 'We have known and worked with the founding team at Pluristyx for many years, and have a great deal of respect for their scientific expertise in cell therapy. Their recent development of an iPSC-based biological assay for organoid manufacturing dovetails with our interest in exploring biological assays more broadly as a product portfolio adjacency.' Article content 'We are excited to continue our support of Dr. Fryer and the entire Pluristyx team,' said Daniel Friedman, Principal at BroadOak Capital Partners. 'Pluristyx is differentiated by its suite of proprietary technologies that directly address some of the most critical scientific challenges of the iPSC field.' Article content iPSCs are unique tools and building blocks for medicines. In addition to applications for innovative new toxicology, safety, and efficacy assays to replace animal models, Pluristyx's products are the ideal universal raw material to produce living medicines to cure currently untreatable diseases. This strategic investment will enable Pluristyx to be the industry leader offering the highest quality stem cells available anywhere. Article content About BioLife Solutions Article content BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit or follow BioLife on LinkedIn and X. Article content About BroadOak Capital Partners Article content BroadOak Capital Partners is a boutique financial institution that provides direct investment and investment banking services to companies in the life science tools, diagnostics, and biopharma services sectors. BroadOak has led or participated in investments in over 70 companies across the life sciences industry. For more information, visit Article content Pluristyx is dedicated to enabling the development of next-generation cell-based tools and therapies. PluriKit™, PluriForm™ Organoids, and PluriBank™ stem cells incorporating safety and tolerance features like FailSafe®, iACT™, and hypoimmune engineering streamline developers' path to the clinic and approval. Pluristyx's iPSC lines, backed by an FDA registered drug master file, with platform genetic engineering are available 'off-the-shelf' along with comprehensive support services to accelerate the creation of novel diagnostics, screening and safety testing, and curative treatments. For more information, visit Article content Article content Article content Article content

National Post
an hour ago
- National Post
Hyperfine Swoop® AI-Powered Portable MRI System Demonstrates 100% Sensitivity for ARIA-E Detection in New Data Presented at the 2025 Alzheimer's Association International Conference
Article content Interim results from the CARE PMR study support the use of ultra-low-field MRI as a triage tool for monitoring patients on amyloid-targeting therapies. Article content TORONTO — Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop ® system—announced promising early results from the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) study presented at the 2025 Alzheimer's Association International Conference in Toronto, Canada. Article content Researchers from the Benzinger Lab at Washington University School of Medicine in St. Louis reported interim results from 31 Alzheimer's patients undergoing Lecanemab therapy. Participants were scanned using the Swoop ® system within one week of their clinical high-field MRI scans, as part of the safety monitoring protocol required by the FDA when it approved Lecanemab. Article content The Swoop ® system achieved 100% sensitivity in detecting mild to moderate ARIA-E, a condition marked by cerebral edema. Researchers note that while ultra-low-field MRI is promising as a triage tool to screen for ARIA-E, high-field MRI may remain necessary for comprehensive evaluation in some cases. Article content Appropriate use guidelines for amyloid-targeting therapies, including Lecanemab and Donanemab, require MRI safety monitoring at multiple, specific intervals throughout the course of therapy. However, regular screening with conventional MRI systems is often hindered by high costs, scheduling delays, and logistical challenges for both patients and caregivers. The Swoop ® system addresses these barriers by offering an affordable, portable imaging solution that is readily available to patients at the point of care, such as neurology offices and infusion clinics. Dr. Tammie Benzinger, principal investigator of the study, noted, 'This research could help alleviate the burden on families and facilities and improve overall access to care. We are hoping to expand the project to Washington University's Medical Campus to include community sites offering infusion therapy for early Alzheimer's disease.' Article content These findings from the CARE PMR study underscore the potential of portable MRI to transform ARIA-E monitoring and expand access to care. The Swoop ® system enables clinicians to confidently detect ARIA-E, while offering patients and caregivers the convenience of point-of-care screening, eliminating the need for separate imaging appointments. 'We are proud to collaborate with leading clinicians and researchers who share our vision of advancing Alzheimer's care through accessible innovation,' said Edmond Knopp, MD, Chief Medical Officer at Hyperfine. Article content The CARE PMR study is a collection of data from multiple sites assessing the clinical utility and workflow benefits of using Swoop ® system images to detect amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients receiving amyloid-targeting therapy. It is funded by the Alzheimer's Association and the American Society of Neuroradiology. Article content The Swoop ® Portable MR Imaging ® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. Article content About Hyperfine, Inc. Article content Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop ® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop ® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit Article content The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc. Article content Forward-Looking Statements Article content This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the 'Company') may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop ® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under 'Risk Factors' therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. Article content Article content Article content Article content Media Contact Article content Article content Devin Zell Article content Article content Hyperfine Article content Article content dzell@ Article content Investor Contact Article content Article content Webb Campbell Article content Article content